Quantitative effects of timolol and hydrochlorothiazide on blood pressure, heart rate and plasma renin activity: results of a double-blind factorial trial in patients with essential hypertension. 1976

J P Chalmers, and J S Horvath, and P I Korner, and D J Tiller, and A J Bune, and J D England, and P J Fletcher

1. The anti-hypertensive actions of timolol and hydrochlorothiazide were analysed in a double-blind 2 x 2 factorial trial in twenty patients with essential hypertension. Each patient went through four phases of 8 weeks in randomized order, receiving timolol alone, hydrochlorothiazide alone, timolol plus hydrochlorothiazide, and placebo. 2. Supine mean arterial pressure fell from 119 mmHg in the placebo phase, to 110 mmHg during the thiazide phase, 106 mmHg during the timolol phase, and to 101 mmHg during the combined timolol plus hydrochlorothiazide phase. 3. Factorial analysis revealed that the hypotensive actions of the beta-receptor-blocking drug and the diuretic were additive, without any synergism or antagonism. 4. Plasma renin activity measured in ng 3 h-1 ml-1 rose from 5-02 in the placebo phase to 9-54 in the diuretic phase, but fell to 1-79 in the beta-receptor blockade. It was unchanged in the combined therapy phase, despite the greater drop in blood pressure. These results suggest that the fall in plasma renin activity during beta-receptor blockade is of little importance in the hypotensive action of beta-receptor-blocking drugs.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. Aminopropanols
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J P Chalmers, and J S Horvath, and P I Korner, and D J Tiller, and A J Bune, and J D England, and P J Fletcher
September 1976, Lancet (London, England),
J P Chalmers, and J S Horvath, and P I Korner, and D J Tiller, and A J Bune, and J D England, and P J Fletcher
March 1984, International journal of clinical pharmacology, therapy, and toxicology,
J P Chalmers, and J S Horvath, and P I Korner, and D J Tiller, and A J Bune, and J D England, and P J Fletcher
August 1986, Australian and New Zealand journal of medicine,
J P Chalmers, and J S Horvath, and P I Korner, and D J Tiller, and A J Bune, and J D England, and P J Fletcher
December 1972, Archives of internal medicine,
J P Chalmers, and J S Horvath, and P I Korner, and D J Tiller, and A J Bune, and J D England, and P J Fletcher
May 1976, The Medical journal of Australia,
J P Chalmers, and J S Horvath, and P I Korner, and D J Tiller, and A J Bune, and J D England, and P J Fletcher
January 1984, Pharmatherapeutica,
J P Chalmers, and J S Horvath, and P I Korner, and D J Tiller, and A J Bune, and J D England, and P J Fletcher
February 1992, Angiology,
J P Chalmers, and J S Horvath, and P I Korner, and D J Tiller, and A J Bune, and J D England, and P J Fletcher
January 1972, Cleveland Clinic quarterly,
J P Chalmers, and J S Horvath, and P I Korner, and D J Tiller, and A J Bune, and J D England, and P J Fletcher
March 1979, Clinical pharmacology and therapeutics,
J P Chalmers, and J S Horvath, and P I Korner, and D J Tiller, and A J Bune, and J D England, and P J Fletcher
August 1980, Endocrinologia japonica,
Copied contents to your clipboard!